{"id":"W4254701901","doi":"10.1200/jco.2012.30.5_suppl.15","title":"Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Placebo; Clinical endpoint; Discontinuation; Prostate cancer; Internal medicine; Docetaxel; Tolerability; Prednisone; Randomization; Hazard ratio; Oncology; Urology; Gastroenterology; Chemotherapy; Cancer; Randomized controlled trial; Androgen deprivation therapy; Adverse effect; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01343849,0.001538304,0.001962132,0.0006664952,0.0003145096,0.001063625,0.001170215,0.001392544,0.003627708],"category_scores_gemma":[0.01082554,0.0005045388,0.005620005,0.0005630187,0.0009824575,0.0009982012,0.0007843502,0.002040181,0.0004077474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008404808,"about_ca_system_score_gemma":0.001454007,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000415938,"about_ca_topic_score_gemma":0.0007285897,"domain_scores_codex":[0.9925166,0.00600795,0.0002326086,0.0004513093,0.0003399969,0.0004515174],"domain_scores_gemma":[0.9847502,0.01102302,0.001647746,0.001085261,0.0003431881,0.001150775],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.956423,0.005305944,0.01125084,0.0003703483,0.004610789,0.0001887027,0.0001417581,0.002412593,0.007257204,0.0001789896,0.0005109849,0.01134887],"study_design_scores_gemma":[0.1920312,0.651916,0.1143115,0.00008354751,0.01402341,0.0004842175,0.0001887569,0.01345444,0.008864203,0.001198959,0.003321205,0.0001226888],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947295,0.001278144,0.001064404,0.0001477764,0.00005117557,0.0008251366,0.001035987,0.00005502456,0.0008128827],"genre_scores_gemma":[0.9958773,0.0002246128,0.001186125,0.0001467753,0.0000753483,0.0007083748,0.001009806,0.00001691641,0.000754648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01343849,"threshold_uncertainty_score":0.07107037,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2240525746293755,"score_gpt":0.516633520639768,"score_spread":0.2925809460103925,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}